A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.
Inclusion Criteria:
Exclusion Criteria:
San Francisco, California 94110, United States
Chapel Hill, North Carolina 27599, United States
Westmead Nsw, New South Wales 2145, Australia
Clayton Vic, Victoria 3168, Australia
Shebin Elkom, Monufia Governorate 35111, Egypt
Cisanello (pisa), 56124, Italy